The growing need for Canadian biopharma and biosimilar companies to demonstrate product value to health technology agencies (HTAs) and payers to gain and maintain access is driving changes to commercialization strategies along the product lifecycle. As decision-making among these stakeholders is increasingly focused on value and outcome measures, there is a need for additional evidence generation beyond traditional randomized clinical trials (RCTs) during the pre-launch phase.

Leveraging real-world evidence (RWE) across the product lifecycle enables manufacturers to fill the evidence gap beyond RCTs to help guide local commercial strategic planning and market access strategy, to provide data-driven insights to proactively inform payer and HTAs decision-making, to maximize payer coverage, and to improve patient outcomes.

The information provided in this piece does not constitute legal or medical advice. Innomar Strategies Inc. and its parent Cencora, Inc. strongly encourage the audience to review available information related to the topics discussed to rely on their own experience and expertise in making decisions related thereto. Further, the contents of this piece are owned by Innomar Strategies, and reproduction is not permitted without the consent of Innomar Strategies.